Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Large Cell Neuroendocrine Carcinoma of the Lung”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Not applicableLooking for participantsNCT06717243
What this trial is testing

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

Who this might be right for
Small Cell Lung CancerLarge Cell Neuroendocrine (NE) TumorsTreatment Failure+3 more
Oncology Center of Biochemical Education And Research 111
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Early research (Phase 1)Ended earlyNCT02500914
What this trial is testing

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Who this might be right for
Small Cell Lung Cancer
Stemcentrx 35
Testing effectiveness (Phase 2)UnknownNCT02943798
What this trial is testing

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Who this might be right for
Pulmonary Large Cell Neuroendocrine Carcinoma
Shanghai Chest Hospital 118
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Early research (Phase 1)Active Not RecruitingNCT03236935
What this trial is testing

Phase Ib of L-NMMA and Pembrolizumab

Who this might be right for
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more
The Methodist Hospital Research Institute 12
Early research (Phase 1)Study completedNCT00003022
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+4 more
Memorial Sloan Kettering Cancer Center
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Testing effectiveness (Phase 2)Looking for participantsNCT06814496
What this trial is testing

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Who this might be right for
MelanomaMedullary Thyroid CancerSinonasal Undifferentiated Carcinoma+8 more
University of Arizona 30
Testing effectiveness (Phase 2)Study completedNCT02936323
What this trial is testing

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Who this might be right for
Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma
Tarveda Therapeutics 89
Not applicableStudy completedNCT03998332
What this trial is testing

Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study

Who this might be right for
Survival Outcomes of Patients With Pulmonary LCNEC
Jaroslaw B. Cwikla, MD, PhD, Professor UWM 132
Early research (Phase 1)Looking for participantsNCT05680922
What this trial is testing

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer Extensive StageLarge Cell Neuroendocrine Carcinoma of the Lung
Legend Biotech USA Inc 41
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals 116
Early research (Phase 1)Ended earlyNCT04254107
What this trial is testing

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Who this might be right for
Non-small Cell Lung CancerGastric CarcinomaGastroesophageal Junction Carcinoma+9 more
Seagen Inc. 133
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Ended earlyNCT02376699
What this trial is testing

Safety Study of SEA-CD40 in Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHodgkin Disease+17 more
Seagen Inc. 159
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT04079712
What this trial is testing

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Who this might be right for
Metastatic Large Cell Neuroendocrine CarcinomaMetastatic Neuroendocrine CarcinomaMetastatic Neuroendocrine Neoplasm+1 more
National Cancer Institute (NCI) 17
Load More Results